Related Experiment Video

Updated: Jan 17, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

349

Emerging Targets in Non-Small Cell Lung Cancer

Jing Wang1, Layana Biglow1, Megan Baumgart1

  • 1Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.

Lung Cancer (Auckland, N.Z.)
|September 15, 2025
PubMed

Insights

Identifying molecular driver mutations in non-small cell lung cancer (NSCLC) has improved patient survival. Ongoing research seeks new targets and therapies to benefit more lung cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Molecular driver mutations are key in non-small cell lung cancer (NSCLC) treatment.
  • Targeted therapies have significantly improved survival for some NSCLC patients.
  • Research is actively identifying new targets to enhance treatment efficacy.

Purpose of the Study:

  • To review novel therapeutic strategies for known NSCLC driver mutations.
  • To present data on emerging molecular targets in NSCLC treatment.

Main Methods:

  • Literature review of recent studies on NSCLC driver mutations and targeted therapies.
  • Analysis of clinical trial data for emerging molecular targets.

Main Results:

  • Several molecular targets have been identified, leading to new therapeutic options.
  • Targeted therapies show improved survival rates in specific NSCLC patient subsets.
  • Emerging targets show promise for broader application in NSCLC treatment.

Conclusions:

  • Targeted therapies based on molecular driver mutations have transformed NSCLC treatment.
  • Continued research into novel molecular targets is crucial for improving outcomes in more patients.
  • Personalized medicine approaches are essential for advancing NSCLC care.
Keywords:
driver mutationsmolecular alterationsnon-small cell lung cancertargeted therapy

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K